P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naive schizophrenia
Xia, Luyao2,3; Wang, Dongmei2,3; Wei, Gaoxia2,3; Wang, Jiesi2,3; Zhou, Huixia2,3; Xu, Hang2,3; Tian, Yang2,3; Dai, Qilong2,3; Xiu, Meihong1; Chen, Dachun1
刊名PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
2021-04-20
卷号107页码:7
关键词Schizophrenia P50 Sensory gating Auditory evoked potential Cognition
ISSN号0278-5846
DOI10.1016/j.pnpbp.2021.110246
产权排序1
文献子类实证研究
英文摘要

Background: Many studies have announced that P50 inhibition defects represent sensory gating deficits in schizophrenia, but studies seldom have searched the correlation between P50 inhibition defects and the psychopathology or cognitive impairment of patients with first-episode, drug naive (FEDN) of schizophrenia. In this study, we investigated the auditory sensory gating deficits in a large number of Han patients with FEDN schizophrenia and their correlation with clinical symptoms and cognitive impairment. Methods: A total of 130 patients with FEDN schizophrenia and 189 healthy controls were recruited in this study. Positive and Negative Syndrome Scale (PANSS) and its five-factor model were used to score the psychopathology of the patients, and P50 inhibition was recorded using the 64-channel electroencephalography (EEG) system. Results: Patients exhibited significantly longer S1 and S2 latency, lower S1 and S2 amplitudes and lower P50 difference than healthy controls (all p < 0.05). Significant correlations existed between S1 latency and PANSS negative symptoms or cognitive factor, P50 ratio and general psychopathology, P50 ratio and PANSS total score, P50 difference and general psychopathology, and P50 difference and PANSS total score (all p < 0.05). Multiple regression analysis revealed that S1 latency, sex, age, and education were contributors to negative symptom score (all p < 0.05). S1 latency, S2 latency, sex, age, and smoking status were contributors to cognitive factor (all p < 0.05). Conclusions: Our results show that patients with FEDN schizophrenia have P50 inhibition defects, which may be related to their psychopathological symptoms and cognitive impairment.

WOS研究方向Neurosciences & Neurology ; Pharmacology & Pharmacy ; Psychiatry
出版者PERGAMON-ELSEVIER SCIENCE LTD
WOS记录号WOS:000617280700016
内容类型期刊论文
源URL[http://ir.psych.ac.cn/handle/311026/38568]  
专题心理研究所_中国科学院心理健康重点实验室
通讯作者Zhang, Xiangyang
作者单位1.Peking Univ, Beijing HuiLongGuan Hosp, Beijing, Peoples R China
2.Chinese Acad Sci, Inst Psychol, CAS Key Lab Mental Hlth, Beijing, Peoples R China
3.Univ Chinese Acad Sci, Dept Psychol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Xia, Luyao,Wang, Dongmei,Wei, Gaoxia,et al. P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naive schizophrenia[J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY,2021,107:7.
APA Xia, Luyao.,Wang, Dongmei.,Wei, Gaoxia.,Wang, Jiesi.,Zhou, Huixia.,...&Zhang, Xiangyang.(2021).P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naive schizophrenia.PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY,107,7.
MLA Xia, Luyao,et al."P50 inhibition defects with psychopathology and cognitive impairment in patients with first-episode drug naive schizophrenia".PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 107(2021):7.
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace